Filing Flows › Macrogenics (MGNX) › Recalls, complaints & regulation
Macrogenics (MGNX): clinical trials
Macrogenics (MGNX) beyond its filings: 5 active clinical trials.
Macrogenics' latest quarter
Macrogenics, Q2 2026: revenue $32.8M (+378% year over year), operating margin -42.2%, net earnings $19.5M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Macrogenics have?
5 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.